about
sameAs
FANTOM5 transcriptome catalog of cellular states based on Semantic MediaWikiGateways to the FANTOM5 promoter level mammalian expression atlasData integration in the era of omics: current and future challengesSTATegra EMS: an Experiment Management System for complex next-generation omics experiments.Accelerating translational research by clinically driven development of an informatics platform--a case study.An atlas of human long non-coding RNAs with accurate 5' ends.Implementation of the CDC translational informatics platform--from genetic variants to the national Swedish Rheumatology Quality RegisterUpdate of the FANTOM web resource: high resolution transcriptome of diverse cell types in mammals.Pediatric systems medicine: evaluating needs and opportunities using congenital heart block as a case study.FANTOM5 CAGE profiles of human and mouse samplesFANTOM5 CAGE profiles of human and mouse reprocessed for GRCh38 and GRCm38 genome assemblies.An integrated expression atlas of miRNAs and their promoters in human and mouse.The FANTOM5 Computation Ecosystem: Genomic Information Hub for Promoters and Active Enhancers.Genome Annotation.Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells.Systems Medicine: from molecular features and models to the clinic in COPD.Linking FANTOM5 CAGE peaks to annotations with CAGEscan.Transcription start site profiling of 15 anatomical regions of the Macaca mulatta central nervous system.Monitoring transcription initiation activities in rat and dog.SCPortalen: human and mouse single-cell centric database.Laboratory biomarkers and frailty: presentation of the FRAILOMIC initiative.Linking FANTOM5 CAGE Peaks To Annotations With CAGEscanGeospatial metadata extraction from product description document applying methods from ontology engineeringUpdate of the FANTOM web resource: expansion to provide additional transcriptome atlasesC1 CAGE detects transcription start sites and enhancer activity at single-cell resolutionrefTSS: A Reference Data Set for Human and Mouse Transcription Start SitesIncidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysisOMIC SIGNATURES IN FRAILTY AND FRAILTY DIAGNOSIS
P50
Q28596481-7FCCC57C-677F-4F8A-A0B9-7334DD51CCF2Q28651260-4987F362-343A-4EF6-8E5A-FD4791D0AD9BQ28655601-F651AEA2-BA5F-414E-A7CD-EBE544A1D578Q33913345-D012F205-404C-4504-8E45-E61880428096Q34155502-564F5857-F78B-4E38-86F8-0E3EC08C3C94Q34552181-E3D6624F-2AB8-4F91-9903-A1FE054D4FF3Q36758706-E190C357-E8EA-4413-B54F-F0CD916E1F11Q37557111-DE07A395-0345-42D4-A388-E46F79D86FFFQ38078204-85EE6BB7-13C8-4E87-B6EA-2CC949FB7052Q38604042-05BE4B58-3EE0-482C-A287-4E649A2280D2Q38604046-176B3AF0-DD41-4404-A77D-B26F47A16773Q38614360-6D145720-382F-4735-8D02-53114E84914AQ38815370-8E45A66A-8822-406F-89A4-7B326C4ACE73Q39146486-01FE7EBC-B720-465D-8C05-3C387D65395EQ41440879-D3631102-BBC2-4DD2-BA4C-DF6D2493DC58Q41731469-17F21525-FFE7-4F71-927C-BC740614245DQ42284915-B63514BA-D727-43BC-A63C-7D7B8AA8F77AQ45843855-77F8325B-14BB-4738-A146-933C8FC15050Q46252848-392D3FA3-8FB4-4A21-B01F-4ADFB237135DQ47143140-A7775531-8407-4036-9020-C3701A972FD6Q48185041-2AC06FA4-1D57-45C8-B684-39A7BFA9EB35Q57403071-8BB5E82C-E216-4B4B-9F78-E9B98C665B6BQ57403089-86DB75E4-49C5-4DED-9B8C-F194EA5082A7Q58587056-43D79ABD-3A2E-4D6F-B01F-6F30AEFC7A76Q61124846-2B31FC22-DA58-46FB-B42E-FE2FEE29411FQ91918983-0F23009A-68AF-4B0E-A1B0-91EBBEDF246EQ93014417-BF11B930-1C95-4A08-B926-4B4AA44AE6C1Q94134077-FB6E00B0-1C0A-4472-82A4-AB80BFF22929
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Imad Abugessaisa
@ast
Imad Abugessaisa
@en
Imad Abugessaisa
@es
Imad Abugessaisa
@nl
Imad Abugessaisa
@sl
type
label
Imad Abugessaisa
@ast
Imad Abugessaisa
@en
Imad Abugessaisa
@es
Imad Abugessaisa
@nl
Imad Abugessaisa
@sl
prefLabel
Imad Abugessaisa
@ast
Imad Abugessaisa
@en
Imad Abugessaisa
@es
Imad Abugessaisa
@nl
Imad Abugessaisa
@sl
P106
P108
P1153
6506529160
P1960
SsPaVCkAAAAJ
P21
P2456
P31
P496
0000-0001-7458-801X
P569
2000-01-01T00:00:00Z